Market Cap 61.28M
Revenue (ttm) 154.90M
Net Income (ttm) -20.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13.04%
Debt to Equity Ratio 15.74
Volume 2,655,808
Avg Vol 3,045,962
Day's Range N/A - N/A
Shares Out 189.85M
Stochastic %K 42%
Beta 1.65
Analysts Hold
Price Target $2.00

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 251 4400
Address:
25 Fenton Main Street, Suite 300, Cary, United States
test1234lctx
test1234lctx Aug. 26 at 7:39 PM
$HRTX has anyone read their 10Q it tells you alot
0 · Reply
Braddog
Braddog Aug. 26 at 6:38 PM
$HRTX IMHO, Heron has 3 options. 1. Sell the whole company 2. Continue as is and hope they can stay liquid when Azurity launches Which could end up in BK 3. Sell Cin. I think Azurity might be interested. They could just sell Cin and not the generic. For it to save Heron I would think it would have to be for $150 or greater. This just sucks
1 · Reply
chance111
chance111 Aug. 26 at 5:10 PM
$HRTX What I am about to post is speculation, but my instincts tell me that it is very possibly true. Unlike some other people who post things that are speculative, but post them as if they are facts, at least I am admitting that this post is speculation and based upon my experiences. I am pretty sure that the management team for heron knows what the judges decision will be regarding cinvanti. Knowing that the ruling will go against them, I am hoping they are smart enough to work out a buyout deal that will save a lot of pain that might be felt by so many people when the negative ruling is announced. I am not sure how badly a negative announcement will be on the share price because it might already be built in, but long term it will definitely hurt unless it is overturned which isn't very likely. Before people jump all over me, this is speculation on my part and could be good or bad depending upon what buyout deal is arranged. More reason to hope for a buyout very soon.
0 · Reply
slayer2408
slayer2408 Aug. 26 at 3:35 PM
$HRTX piece of shit
2 · Reply
Highfade
Highfade Aug. 26 at 2:15 PM
$HRTX as much as I like to beat this dead heron….it looks like the setup is in for legitimate short squeeze in next couple weeks or so….25% short float, 80% institutional ownership, .32 PPS and +~ 12 days to cover. however it’s going to to take a catalyst (CC ) or some significant increase in buying volume….( a fund or 2 running this up like the Avis Car Rental scenario… If it does happen most likely nothing to do with CC but that’s probably a good thing. GLTA 😜
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 26 at 10:59 AM
3 · Reply
Braddog
Braddog Aug. 26 at 1:49 AM
$HRTX @milans100 Hello Have you left us?
1 · Reply
Zardiw
Zardiw Aug. 25 at 11:26 PM
#DDAmanda Pick Alerts for August 26, 2026: $OSRH, $RMSG, $FBDT, $HRTX, $ADCT https://DDAmanda.com
0 · Reply
Tacto
Tacto Aug. 25 at 11:02 PM
$HRTX 46,738,152 - 43,242,611 = 3,495,541 Very interesting. That 3.5M is precisely what they are now swapping around like a f'n hot potato in the shorting pool. The bad guys obviously have bitten off more than they can chew, and now they're gonna choke on it... LOL . . .
0 · Reply
Tacto
Tacto Aug. 25 at 10:54 PM
$HRTX Short stains' stop-losses are currently congregated around the $0.40 mark, and Upper BB is way up at $0.57 Chandelier Exit (Short, 3 ATRs) = $0.40 Upper Bollinger Band = $0.57 . .
0 · Reply
Latest News on HRTX
Heron Therapeutics Earnings Call Transcript: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 16 days ago

Heron Therapeutics Earnings Call Transcript: Q2 2026


Heron Therapeutics Earnings release: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 16 days ago

Heron Therapeutics Earnings release: Q2 2026


Heron Therapeutics Quarterly report: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 16 days ago

Heron Therapeutics Quarterly report: Q2 2026


Heron Therapeutics Transcript: AGM 2026

Jun 11, 2026, 9:00 AM EDT - 2 months ago

Heron Therapeutics Transcript: AGM 2026


Heron Therapeutics downgraded to Hold from Buy at Needham

2026-06-02T20:07:25.000Z - 3 months ago

Heron Therapeutics downgraded to Hold from Buy at Needham


Heron Therapeutics reports Q1 EPS (4c), consensus (2c)

2026-05-11T16:41:43.000Z - 3 months ago

Heron Therapeutics reports Q1 EPS (4c), consensus (2c)


Heron Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Heron Therapeutics Earnings Call Transcript: Q1 2026


Heron Therapeutics Earnings release: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Heron Therapeutics Earnings release: Q1 2026


Heron Therapeutics Quarterly report: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Heron Therapeutics Quarterly report: Q1 2026


Heron Therapeutics Slides: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Heron Therapeutics Slides: Q1 2026


Heron Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Heron Therapeutics Earnings Call Transcript: Q4 2025


Heron Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Heron Therapeutics Annual report: Q4 2025


Heron Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Heron Therapeutics Earnings release: Q4 2025


Heron Therapeutics Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Heron Therapeutics Slides: Q4 2025


Heron Therapeutics reports Q4 EPS (2c) vs 2c last year

2026-02-26T13:22:25.000Z - 6 months ago

Heron Therapeutics reports Q4 EPS (2c) vs 2c last year


Heron Therapeutics sees FY26 revenue $173M-$183M

2026-02-26T13:22:12.000Z - 6 months ago

Heron Therapeutics sees FY26 revenue $173M-$183M


Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

2026-01-09T14:35:13.000Z - 8 months ago

Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M


Heron Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Heron Therapeutics Earnings Call Transcript: Q3 2025


Heron Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Heron Therapeutics Quarterly report: Q3 2025


Heron Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Heron Therapeutics Earnings release: Q3 2025


Heron Therapeutics Slides: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Heron Therapeutics Slides: Q3 2025


Heron Therapeutics reports Q3 EPS (10c), consensus (1c)

2025-11-04T13:05:21.000Z - 10 months ago

Heron Therapeutics reports Q3 EPS (10c), consensus (1c)


Heron Therapeutics Proxy statement: Proxy Filing

Sep 19, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics files $125M mixed securities shelf

2025-09-09T21:15:15.000Z - 1 year ago

Heron Therapeutics files $125M mixed securities shelf


Heron Therapeutics Proxy statement: Proxy Filing

Sep 9, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics adopts tax benefits preservation plan

2025-08-15T11:50:16.000Z - 1 year ago

Heron Therapeutics adopts tax benefits preservation plan


Heron Therapeutics Earnings Call Transcript: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q2 2025


Heron Therapeutics Quarterly report: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Quarterly report: Q2 2025


Heron Therapeutics Earnings release: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Earnings release: Q2 2025


Heron Therapeutics Slides: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Slides: Q2 2025


Heron Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q1 2025


Heron Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Earnings release: Q1 2025


Heron Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Quarterly report: Q1 2025


Heron Therapeutics Slides: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Slides: Q1 2025


Heron Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q4 2024


Heron Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Annual report: Q4 2024


Heron Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings release: Q4 2024


Heron Therapeutics Slides: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Slides: Q4 2024


U.S. District Court Upholds Validity of CINVANTI® Patents

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents


Heron Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q3 2024


Heron Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Quarterly report: Q3 2024


Heron Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings release: Q3 2024


Heron Therapeutics Slides: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Slides: Q3 2024


Heron Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q2 2024


Heron Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Quarterly report: Q2 2024


Heron Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings release: Q2 2024


Heron Therapeutics Slides: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Slides: Q2 2024


Heron Therapeutics Transcript: Investor Day 2024

May 15, 2024, 9:30 AM EDT - 2 years ago

Heron Therapeutics Transcript: Investor Day 2024


Heron Therapeutics Slides: FY 2024

May 15, 2024, 9:30 AM EDT - 2 years ago

Heron Therapeutics Slides: FY 2024


Heron Therapeutics Earnings Call Transcript: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q1 2024


Heron Therapeutics Quarterly report: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Quarterly report: Q1 2024


Heron Therapeutics Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Earnings release: Q1 2024


Heron Therapeutics Slides: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Slides: Q1 2024


Heron Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Earnings Call Transcript: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q4 2023


Heron Therapeutics Annual report: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Annual report: Q4 2023


Heron Therapeutics Earnings release: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings release: Q4 2023


Heron Therapeutics Slides: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Slides: Q4 2023


Heron Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Heron Therapeutics Earnings Call Transcript: Q3 2023


Heron Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Heron Therapeutics Quarterly report: Q3 2023


Heron Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Heron Therapeutics Earnings release: Q3 2023


Heron Therapeutics Slides: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Heron Therapeutics Slides: Q3 2023


Heron Therapeutics Registration statement: Registration Filing

Aug 23, 2023, 8:00 AM EDT - 3 years ago

Heron Therapeutics Registration statement: Registration Filing


Heron Therapeutics Earnings Call Transcript: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Earnings Call Transcript: Q2 2023


Heron Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Quarterly report: Q2 2023


Heron Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Earnings release: Q2 2023


Heron Therapeutics Slides: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Slides: Q2 2023


test1234lctx
test1234lctx Aug. 26 at 7:39 PM
$HRTX has anyone read their 10Q it tells you alot
0 · Reply
Braddog
Braddog Aug. 26 at 6:38 PM
$HRTX IMHO, Heron has 3 options. 1. Sell the whole company 2. Continue as is and hope they can stay liquid when Azurity launches Which could end up in BK 3. Sell Cin. I think Azurity might be interested. They could just sell Cin and not the generic. For it to save Heron I would think it would have to be for $150 or greater. This just sucks
1 · Reply
chance111
chance111 Aug. 26 at 5:10 PM
$HRTX What I am about to post is speculation, but my instincts tell me that it is very possibly true. Unlike some other people who post things that are speculative, but post them as if they are facts, at least I am admitting that this post is speculation and based upon my experiences. I am pretty sure that the management team for heron knows what the judges decision will be regarding cinvanti. Knowing that the ruling will go against them, I am hoping they are smart enough to work out a buyout deal that will save a lot of pain that might be felt by so many people when the negative ruling is announced. I am not sure how badly a negative announcement will be on the share price because it might already be built in, but long term it will definitely hurt unless it is overturned which isn't very likely. Before people jump all over me, this is speculation on my part and could be good or bad depending upon what buyout deal is arranged. More reason to hope for a buyout very soon.
0 · Reply
slayer2408
slayer2408 Aug. 26 at 3:35 PM
$HRTX piece of shit
2 · Reply
Highfade
Highfade Aug. 26 at 2:15 PM
$HRTX as much as I like to beat this dead heron….it looks like the setup is in for legitimate short squeeze in next couple weeks or so….25% short float, 80% institutional ownership, .32 PPS and +~ 12 days to cover. however it’s going to to take a catalyst (CC ) or some significant increase in buying volume….( a fund or 2 running this up like the Avis Car Rental scenario… If it does happen most likely nothing to do with CC but that’s probably a good thing. GLTA 😜
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 26 at 10:59 AM
3 · Reply
Braddog
Braddog Aug. 26 at 1:49 AM
$HRTX @milans100 Hello Have you left us?
1 · Reply
Zardiw
Zardiw Aug. 25 at 11:26 PM
#DDAmanda Pick Alerts for August 26, 2026: $OSRH, $RMSG, $FBDT, $HRTX, $ADCT https://DDAmanda.com
0 · Reply
Tacto
Tacto Aug. 25 at 11:02 PM
$HRTX 46,738,152 - 43,242,611 = 3,495,541 Very interesting. That 3.5M is precisely what they are now swapping around like a f'n hot potato in the shorting pool. The bad guys obviously have bitten off more than they can chew, and now they're gonna choke on it... LOL . . .
0 · Reply
Tacto
Tacto Aug. 25 at 10:54 PM
$HRTX Short stains' stop-losses are currently congregated around the $0.40 mark, and Upper BB is way up at $0.57 Chandelier Exit (Short, 3 ATRs) = $0.40 Upper Bollinger Band = $0.57 . .
0 · Reply
Tacto
Tacto Aug. 25 at 10:49 PM
$HRTX Reported short interest for August 14th was just made public, and it rose from 43,242,611 to 46,738,152 No wonder the goons are stalling, and they even moved 3.4M into the shorting pool this morning, then took availability back down to ZERO only minutes later, and that's now the third time they've done that laundering cycle in recent days, and twice today Without any availability in the shorting pool, those crime syndicate operators can't generate much fake volume, and you saw the result of that today . .
0 · Reply
chance111
chance111 Aug. 25 at 6:45 PM
$HRTX People on here are finally realizing the obvious and have stopped posting their nonsense. Heron will continue to move sideways until next earnings unless there is a buyout or positive news on cinvanti. That good news can happen, but everyone should be prepared for it not to happen. Continue to hope for a buyout of any kind just to end the misery. I doubt if the next earnings report will change anything in a positive direction. Even though heron is not dropping significantly, everyone invested in it is losing money because their money could grow if invested in better stocks. The only reason to stick with heron is because of its insanely low price and the chance for a buyout of any kind. That is the only reason I remain a shareholder.
0 · Reply
taneraydar
taneraydar Aug. 25 at 5:58 PM
$HRTX in 5k€
0 · Reply
Highfade
Highfade Aug. 25 at 5:57 PM
$HRTX settle on in….
0 · Reply
Sdwg
Sdwg Aug. 25 at 5:05 PM
$HRTX hope you guys get the miracle you are hoping for....glta
0 · Reply
slayer2408
slayer2408 Aug. 25 at 2:15 PM
$HRTX pos
0 · Reply
Tacto
Tacto Aug. 25 at 10:13 AM
$HRTX Shorting pool availability is back to ZERO, so the 3.5M thing was just fraud. They swap it around, just like we learned from 'Den of Thieves'. It's pretty much the same as laundering, and financial instruments are financial instruments, no matter how phony, so... . .
0 · Reply
Tacto
Tacto Aug. 24 at 11:17 PM
$HRTX First came the initial appearance of a record for the Phase 4 clinical trial on the official FDA clinicaltrials .gov site last week, for the Zynrelef study sponsored by Henry Ford Health, and now Heron Therapeutics appears today as a Silver Sponsor for the Michigan Orthopaedic Society meeting in January, with the Michigan Orthopaedic Society being largely supported by Henry Ford Health https://stocktwits.com/Tacto/message/662632173 . .
0 · Reply
Tacto
Tacto Aug. 24 at 10:58 PM
$HRTX Did the bad guys cover 3.5M shorts, or did they just pull it out of their rear end to make availability in the shorting pool jump from zero to 3.5M... . .
0 · Reply
Ckwoods
Ckwoods Aug. 24 at 7:17 PM
$HRTX say they do sell Cinvanti, what type of multiple does Zyn/Aponvie bring for a sale?
1 · Reply
Ckwoods
Ckwoods Aug. 24 at 6:57 PM
$HRTX I’m pretty concerned with the outlook AI gives. I think the biggest question will be if Azurity launches at risk. If they don’t that’s going to be huge to allow Heron enough time to make payments for debt and run us afloat. If they launch, then the timeline moves up quickly for a sale. Unfortunately we will likely be a distressed sale. It seems like the appeal will go into next year and possible a decision could be late 2027. As some have mentioned the best solution at this point is to sell Cinvanti to Azurity. Obviously that will depend on how convinced either side is on a generic launch. But a sale could allow Heron to pay off its debts. The most concerning folks for us retail is the debt that Hercules and Rubric still hold. Both will want to take Heron off the exchange if able sell its products to cover their debt. It’s the first time I feel bankruptcy is a real possibility. We need CC to save us at this point and produce a miracle.
2 · Reply
DAP89
DAP89 Aug. 24 at 6:20 PM
$HRTX triple bottom at .30. FYI
0 · Reply